Edition:
United States

VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

0.45USD
3:59pm EST
Change (% chg)

$-0.02 (-4.87%)
Prev Close
$0.48
Open
$0.46
Day's High
$0.50
Day's Low
$0.45
Volume
128,940
Avg. Vol
135,745
52-wk High
$1.38
52-wk Low
$0.38

Chart for

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 0.46
Market Cap(Mil.): $50.48
Shares Outstanding(Mil.): 105.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

BRIEF-Vivus Announces Change In Leadership

* VIVUS INC - BOARD MEMBER THOMAS B. KING APPOINTED INTERIM CEO

Dec 26 2017

BRIEF-Vivus reports third quarter 2017 financial results

* Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​

Nov 07 2017

BRIEF-VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea

* VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​

Sep 05 2017

BRIEF-Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material

* Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus

Sep 01 2017

BRIEF-Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation

* Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation

Aug 30 2017

Earnings vs. Estimates